Get the Stockscreener App
9.00
0.45%
0.04
After Hours:
9.00
Aura Biosciences Inc stock is traded at $9.00, with a volume of 285.04K.
It is up +0.45% in the last 24 hours and down -17.58% over the past month.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$8.96
Open:
$9.01
24h Volume:
285.04K
Relative Volume:
1.51
Market Cap:
$447.81M
Revenue:
-
Net Income/Loss:
$-76.41M
P/E Ratio:
-4.50
EPS:
-2
Net Cash Flow:
$-64.56M
1W Performance:
+2.86%
1M Performance:
-17.58%
6M Performance:
+28.02%
1Y Performance:
+12.64%
1-Day Range:
$8.915
$9.11
1-Week Range:
$8.71
$9.273
52-Week Range:
$6.63
$12.38
Aura Biosciences Inc Stock (AURA) Company Profile
Name
Aura Biosciences Inc
Sector
Industry
Phone
(617)500-8864
Address
80 GUEST STREET, BOSTON
Compare AURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
9.00 | 447.81M | 0 | -76.41M | -64.56M | -2.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-24 | Initiated | H.C. Wainwright | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jul-19-22 | Initiated | JMP Securities | Mkt Outperform |
Aura Biosciences Inc Stock (AURA) Latest News
Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference - GlobeNewswire
Aura Biosciences CEO to Present at Evercore ISI HealthCONx Conference | AURA Stock News - StockTitan
Teladoc (TDOC) Harnesses AI for Diabetes Care, Stock Rises 6.7% - MSN
When (AURA) Moves Investors should Listen - Stock Traders Daily
Aura Biosciences' chief medical officer sells $110,663 in stock By Investing.com - Investing.com Nigeria
Aura Biosciences' chief medical officer sells $110,663 in stock - Investing.com
HC Wainwright Forecasts Higher Earnings for Aura Biosciences - Defense World
HC Wainwright Has Bullish Forecast for AURA FY2024 Earnings - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update - MarketBeat
Aura Biosciences’ (AURA) Buy Rating Reiterated at HC Wainwright - Defense World
What is Leerink Partnrs’ Estimate for AURA FY2024 Earnings? - Defense World
Leerink Partnrs Has Strong Forecast for AURA FY2024 Earnings - MarketBeat
Citadel Advisors LLC Reduces Stake in Aura Biosciences Inc - GuruFocus.com
Brokerages Set Aura Biosciences, Inc. (NASDAQ:AURA) Target Price at $23.00 - Defense World
HC Wainwright Reaffirms Buy Rating for Aura Biosciences (NASDAQ:AURA) - MarketBeat
Aura Biosciences Reports Q3 Financial Results - TipRanks
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study - MSN
Aura Biosciences : Reports Third Quarter 2024 Financial Results and Business Highlights Form 8 K - Marketscreener.com
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
Aura Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of "Buy" from Analysts - MarketBeat
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema - The Manila Times
One Aura Biosciences Insider Raised Stake By 232% In Previous Year - Yahoo Finance
Short Interest in Aura Biosciences, Inc. (NASDAQ:AURA) Decreases By 8.7% - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $98,808.00 in Stock - MarketBeat
Aura Biosciences VP sells shares worth $5,938 By Investing.com - Investing.com Australia
Aura Biosciences CEO Elisabet de los Pinos sells $98,787 in stock By Investing.com - Investing.com South Africa
Aura Biosciences CEO Elisabet de los Pinos sells $98,787 in stock - Investing.com
Aura Biosciences VP sells shares worth $5,938 - Investing.com
Don't Ignore The Insider Selling In Aura Biosciences - Simply Wall St
Aura Biosciences (NASDAQ:AURA) Stock Price Down 4.9% After Insider Selling - Defense World
Aura Biosciences CFO Julie Feder sells shares worth $302,361 - Investing.com India
Aura Biosciences (NASDAQ:AURA) Trading Down 4.9% on Insider Selling - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) CFO Sells $302,325.93 in Stock - MarketBeat
Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value - Seeking Alpha
Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Average Price Target from Analysts - Defense World
Long Term Trading Analysis for (AURA) - Stock Traders Daily
Aura Biosciences (NASDAQ:AURA) PT Raised to $22.00 at HC Wainwright - Defense World
Aura Biosciences stock hits 52-week high at $12.38 By Investing.com - Investing.com Australia
Aura Biosciences CEO sells $300,838 in stock By Investing.com - Investing.com Australia
Aura Biosciences reports promising early trial results - Investing.com India
Insider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells 24,992 Shares of Stock - MarketBeat
Aura Biosciences CEO sells $300,838 in stock - Investing.com
Aura Biosciences, Inc. (NASDAQ:AURA) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Aura Biosciences' Shares Touch 52-Week High on Positive Cancer Drug Data - MarketWatch
Aura Biosciences (NASDAQ:AURA) Hits New 12-Month High After Analyst Upgrade - MarketBeat
Aura Biosciences stock hits 52-week high at $12.38 - Investing.com
Aura Biosciences Inc Stock (AURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):